Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Nivalis Therapeutics (NVLS) Presents at Rodman & Renshaw Conference

Boulder, Colorado-based Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is discovering solutions for cystic fibrosis. The company is developing a class of disease-modifying therapies designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell-signaling effects that are implicated in the pathophysiology of cystic fibrosis (CF).The company’s lead candidate, N91115 initially targets patients with the F508del mutation, the most common disease causing mutation in CF. For more information, visit the company’s website

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.